Bridging Gaps to Translate Plasma Alzheimer's Disease Biomarkers to Diverse Populations
openNIA - National Institute on Aging
Project Summary/Abstract
Plasma biomarkers for Alzheimer’s disease (AD) and related dementias (ADRDs) hold promise as accessible,
affordable, and scalable tools for widespread use to support the detection, diagnosis, and care of patients
affected by ADRDs. However, critical knowledge gaps remain in understanding plasma biomarker performance
in broadly representative cohorts with the full spectrum of risk factors and systemic diseases seen in general
populations to guide clinical and research use. Further, access to plasma biomarkers in sub-Saharan Africa
(sSA), the region anticipated to have the fastest growth in older adults globally, remains a key barrier, and data
to inform use in sSA populations is sorely lacking. The overarching research goal of this project is to address
these gaps to advance plasma biomarkers towards appropriate use in populations in the US and in sSA. To do
so, this proposal will leverage available data in two large, prospective population-based cohorts with available
ADRD plasma biomarkers and deep-phenotyping of the full spectrum of risk factors and systemic diseases
seen in the population: the Framingham Heart Study (FHS; n=2543) and the Uganda Aging Cohort Study
(UACS; n=560). Specifically, Aim 1 proposes to identify demographic, lifestyle, genetic, and systemic diseases
associated with elevated plasma biomarkers in population cohorts in the US and Uganda. Aim 2 will assess the
validity of measuring ADRD biomarkers using dried plasma spots in Uganda as a new method to expand
access to remote and resource-limited settings. Aim 3 intends to use 12-year follow-up data in the FHS to
determine plasma biomarker performance in predicting incident dementia, and to develop a parsimonious
ADRD risk prediction model using multimodal machine learning to optimize risk stratification in the US.
In this K08 career development award, Dr. Jeremy Tanner, a behavioral neurologist and Assistant Professor at
the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at the University of Texas Health
San Antonio, proposes to use this research as a vehicle to develop translational research skills. His
overarching career goal is to become a leader in the clinical translation of biomarkers to improve early
detection, enable more accurate diagnosis, and guide precision care for individuals affected by ADRDs
globally, including in resource-limited settings. Through the K08 award, Dr. Tanner aims to achieve these
specific training objectives: 1) To develop expertise in AD fluid biomarkers; 2) To gain specialized
competencies in conducting research in sSA populations and in health disparities; and 3) To acquire advanced
statistical skills in (a) longitudinal data analysis and (b) applying machine learning to harness multimodal data
to answer scientific questions. To achieve these goals and research independence, Dr. Tanner has assembled
a stellar cross-disciplinary mentorship team of international experts in each area led by his primary mentor, Dr.
Sudha Seshadri, a world leader in neuroepidemiology, biomarkers, and multimodal analyses.
Up to $163K
health research